These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 31551414)
1. Identification of the PTEN-ARID4B-PI3K pathway reveals the dependency on ARID4B by PTEN-deficient prostate cancer. Wu RC; Young IC; Chen YF; Chuang ST; Toubaji A; Wu MY Nat Commun; 2019 Sep; 10(1):4332. PubMed ID: 31551414 [TBL] [Abstract][Full Text] [Related]
2. Downregulation of ARID4A and ARID4B promote tumor progression and directly regulated by microRNA-30d in patient with prostate cancer. Liang YK; Han ZD; Lu JM; Liu ZZ; Zhuo YJ; Zhu XJ; Chen JX; Ye JH; Liang YX; He HC; Zhong WD J Cell Biochem; 2018 Sep; 119(9):7245-7255. PubMed ID: 29797600 [TBL] [Abstract][Full Text] [Related]
3. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis. Tan M; Xu J; Siddiqui J; Feng F; Sun Y Mol Cancer; 2016 Dec; 15(1):81. PubMed ID: 27955654 [TBL] [Abstract][Full Text] [Related]
4. Interplay Among PI3K/AKT, PTEN/FOXO and AR Signaling in Prostate Cancer. Yan Y; Huang H Adv Exp Med Biol; 2019; 1210():319-331. PubMed ID: 31900915 [TBL] [Abstract][Full Text] [Related]
5. PTEN-deficient cancers depend on PIK3CB. Wee S; Wiederschain D; Maira SM; Loo A; Miller C; deBeaumont R; Stegmeier F; Yao YM; Lengauer C Proc Natl Acad Sci U S A; 2008 Sep; 105(35):13057-62. PubMed ID: 18755892 [TBL] [Abstract][Full Text] [Related]
6. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Fang J; Ding M; Yang L; Liu LZ; Jiang BH Cell Signal; 2007 Dec; 19(12):2487-97. PubMed ID: 17826033 [TBL] [Abstract][Full Text] [Related]
7. PTEN in Chromatin Remodeling. Yang J; Yin Y Cold Spring Harb Perspect Med; 2020 Feb; 10(2):. PubMed ID: 31570373 [TBL] [Abstract][Full Text] [Related]
8. Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells. Kikuno N; Shiina H; Urakami S; Kawamoto K; Hirata H; Tanaka Y; Majid S; Igawa M; Dahiya R Int J Cancer; 2008 Aug; 123(3):552-60. PubMed ID: 18431742 [TBL] [Abstract][Full Text] [Related]
9. AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis. Li N; Xue W; Yuan H; Dong B; Ding Y; Liu Y; Jiang M; Kan S; Sun T; Ren J; Pan Q; Li X; Zhang P; Hu G; Wang Y; Wang X; Li Q; Qin J J Clin Invest; 2017 Apr; 127(4):1284-1302. PubMed ID: 28319045 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of the phosphatidylinositol 3'-kinase pathway promotes autocrine Fas-induced death of phosphatase and tensin homologue-deficient prostate cancer cells. Bertram J; Peacock JW; Tan C; Mui AL; Chung SW; Gleave ME; Dedhar S; Cox ME; Ong CJ Cancer Res; 2006 May; 66(9):4781-8. PubMed ID: 16651432 [TBL] [Abstract][Full Text] [Related]
12. Proproliferative function of adaptor protein GRB10 in prostate carcinoma. Khan MI; Al Johani A; Hamid A; Ateeq B; Manzar N; Adhami VM; Lall RK; Rath S; Sechi M; Siddiqui IA; Choudhry H; Zamzami MA; Havighurst TC; Huang W; Ntambi JM; Mukhtar H FASEB J; 2019 Mar; 33(3):3198-3211. PubMed ID: 30379590 [TBL] [Abstract][Full Text] [Related]
13. [Role of PTEN protein in multidrug resistance of prostate cancer cells]. Sherbakova EA; Stromskaia TP; Rybalkina EIu; Kalita OV; Stavrovskaia AA Mol Biol (Mosk); 2008; 42(3):487-93. PubMed ID: 18702307 [TBL] [Abstract][Full Text] [Related]
14. KDM5B Is Essential for the Hyperactivation of PI3K/AKT Signaling in Prostate Tumorigenesis. Li G; Kanagasabai T; Lu W; Zou MR; Zhang SM; Celada SI; Izban MG; Liu Q; Lu T; Ballard BR; Zhou X; Adunyah SE; Matusik RJ; Yan Q; Chen Z Cancer Res; 2020 Nov; 80(21):4633-4643. PubMed ID: 32868382 [TBL] [Abstract][Full Text] [Related]
15. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells. Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633 [TBL] [Abstract][Full Text] [Related]
16. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453 [TBL] [Abstract][Full Text] [Related]
17. Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/AKT pathway in lung cancer. De Marco C; Laudanna C; Rinaldo N; Oliveira DM; Ravo M; Weisz A; Ceccarelli M; Caira E; Rizzuto A; Zoppoli P; Malanga D; Viglietto G PLoS One; 2017; 12(6):e0178865. PubMed ID: 28662101 [TBL] [Abstract][Full Text] [Related]
18. Deregulated PTEN/PI3K/AKT/mTOR signaling in prostate cancer: Still a potential druggable target? Braglia L; Zavatti M; Vinceti M; Martelli AM; Marmiroli S Biochim Biophys Acta Mol Cell Res; 2020 Sep; 1867(9):118731. PubMed ID: 32360668 [TBL] [Abstract][Full Text] [Related]
19. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Cully M; You H; Levine AJ; Mak TW Nat Rev Cancer; 2006 Mar; 6(3):184-92. PubMed ID: 16453012 [TBL] [Abstract][Full Text] [Related]
20. Cholesterol biogenesis is a PTEN-dependent actionable node for the treatment of endocrine therapy-refractory cancers. Kaysudu I; Gungul TB; Atici S; Yilmaz S; Bayram E; Guven G; Cizmecioglu NT; Sahin O; Yesiloz G; Haznedaroglu BZ; Cizmecioglu O Cancer Sci; 2023 Nov; 114(11):4365-4375. PubMed ID: 37706278 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]